Core Viewpoint - The company has received a laboratory accreditation certificate from the China National Accreditation Service for Conformity Assessment (CNAS), which enhances its testing capabilities and credibility in the market [1][2]. Group 1: Basic Information - The accredited entity is the Yongzhen Green Energy Materials Research Institute (Changzhou) Co., Ltd. Testing Center [1]. - The registration number for the accreditation is CNAS L23913, effective from August 21, 2025, to August 20, 2031 [1]. - The certificate confirms compliance with ISO/IEC 17025:2017 standards, indicating the center's capability to perform the services listed in the certificate's annex [1]. Group 2: Impact on the Company - The CNAS accreditation signifies that the testing center's management and technical capabilities have been recognized at both national and international levels [2]. - This recognition is expected to enhance product quality assurance, strengthen product R&D capabilities, and increase customer trust and recognition of the company [2]. - The accreditation is anticipated to improve the company's overall competitiveness and support sustainable high-quality development [2].

注册号：CNAS L23913 证券代码：603381 证券简称：永臻股份 公告编号：2025-049 永臻科技股份有限公司 关于全资子公司获得中国合格评定国家认可委员会 （CNAS）实验室认可证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 永臻科技股份有限公司（以下简称"公司"）全资子公司永臻绿色能源材料 研究院（常州）有限公司（以下简称"永臻研究院"）于近日收到中国合格评定 国家认可委员会（英文名称为"China National Accreditation Service for Conformity Assessment"，以下简称"CNAS"）授予的实验室认可证书，现将相关事宜公 告如下： 一、基本情况 获证机构名称：永臻绿色能源材料研究院（常州）有限公司测试中心 生效日期：2025-08-21 截止日期：2031-08-20 证书内容：永臻绿色能源材料研究院（常州）有限公司测试中心符合ISO/IEC 验室能力认可准则》）的要求，具备承担本证书附件所列服务能力，予以认可。 二、对公司的影响及风险提示 CN ...

Core Viewpoint - Yongzhen Co., Ltd. (603381.SH) announced that its wholly-owned subsidiary, Yongzhen Green Energy Materials Research Institute (Changzhou) Co., Ltd. has recently received a laboratory accreditation certificate from the China National Accreditation Service for Conformity Assessment (CNAS) [1] Group 1 - CNAS is recognized as an authoritative body for the evaluation of conformity assessment organizations, laboratories, inspection institutions, and verification bodies in China [1] - The accreditation by CNAS is based on the regulations of the "Certification and Accreditation Regulations of the People's Republic of China" and the "Supervision and Management Measures for Accreditation Institutions" [1] - CNAS plays a significant role in international recognition activities and is a member of the International Laboratory Accreditation Cooperation (ILAC) and the Asia-Pacific Accreditation Cooperation (APAC) mutual recognition agreements [1]

Core Viewpoint - Zhongjing Wanshi Pharmaceutical's testing center has received the CNAS laboratory accreditation, marking its entry into the international laboratory mutual recognition framework, which enhances the quality and credibility of traditional Chinese medicine [1][3]. Group 1: CNAS Accreditation - CNAS accreditation is one of the highest authorities in laboratory testing capabilities in China, aligning with international standards such as ISO/IEC 17025, providing international credibility to the company's testing data [3]. - The accreditation allows the company to achieve mutual recognition in over 100 countries and regions, enhancing its core competitiveness and global expansion opportunities [3]. Group 2: Testing Capabilities and Innovations - The testing center is equipped with advanced detection equipment, including ICP-MS, LC-MS, and GC-MS, focusing on precision, efficiency, and rigor to ensure drug quality and safety [3]. - The center has published six papers in national core journals and holds over ten patents, demonstrating its commitment to innovation and high-standard testing services [3]. Group 3: Quality Management and Standards - Zhongjing Wanshi Pharmaceutical emphasizes quality system construction and has participated in drafting quality standards for various traditional Chinese medicine products, establishing 19 industry standards and norms [5]. - The company has implemented a comprehensive quality control mechanism from seedling to consumer, continuously improving drug standardization management [5]. - The quality technology leader stated that CNAS recognition is both an affirmation of the existing system and a motivation for future improvements, aiming to provide higher quality and more reliable traditional Chinese medicine products [5].

Core Viewpoint - East Asia Pharmaceutical (605177) announced that its wholly-owned subsidiary, Hangzhou Shanli Biomedical Technology Co., Ltd., has recently obtained the laboratory accreditation certificate from the China National Accreditation Service for Conformity Assessment, which enhances the company's credibility and competitive edge in the market [1] Group 1 - The accreditation certificate is effective from May 20, 2025, to May 19, 2031, indicating a long-term recognition of the laboratory's management and technical capabilities [1] - This recognition allows Hangzhou Shanli's analysis laboratory to conduct testing according to national standards, thereby improving product quality and research capabilities [1] - The accreditation is expected to enhance customer trust and contribute to the company's high-quality development, although it will not have a significant impact on the company's current performance [1]

Core Viewpoint - The successful acquisition of the CNAS laboratory accreditation by the National Energy Investment Group Baiyin Hohhot Coal Industry Company signifies a major milestone in enhancing the company's quality management and testing capabilities, supporting its journey towards high-quality development [1][2]. Group 1: Laboratory Accreditation - The laboratory received the CNAS accreditation certificate, indicating that its quality management and testing capabilities meet national standards [1]. - The preparation for the CNAS certification involved systematic work, including the development of system documents, validation of testing methods, and personnel training [1]. - The evaluation by the expert group included a comprehensive assessment of the laboratory's management system, environmental facilities, testing processes, and quality control [1]. Group 2: Testing Capabilities - The expert group conducted on-site evaluations of seven key testing projects, including coal calorific value, carbon and hydrogen content, ash content, volatile matter, total moisture, and sulfur [1]. - The laboratory's technical capabilities, professional qualifications of personnel, and hardware facilities received high praise from the expert group [1]. Group 3: Future Directions - The company aims to leverage this accreditation as a new starting point to enhance technological innovation and improve testing accuracy [2]. - There is a commitment to continuously optimize management processes and introduce advanced testing technologies and methods [2]. - The company intends to deepen its expertise in coal quality testing and establish a more exemplary quality benchmark in the industry [2].